Science News
from research organizations

Research may provide new targets for inflammatory bowel diseases therapies

Date:
June 15, 2015
Source:
American Gastroenterological Association
Summary:
Modifying the small white blood cells that protect against disease might help treat immune disorders, according to a study. Specifically, researchers found that modulation of B lymphocyte function may be a means of regulating T lymphocyte function to treat immune-mediated disorders, including inflammatory bowel diseases (IBD).
Share:
FULL STORY

Modifying the small white blood cells that protect against disease might help treat immune disorders, according to a study1 published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association. Specifically, researchers found that modulation of B lymphocyte function may be a means of regulating T lymphocyte function to treat immune-mediated disorders, including inflammatory bowel diseases (IBD).

Researchers uncovered the following pathway: gut bacteria stimulate intestinal B lymphocytes to release interleukin (IL)-10 that, in turn, induces development of regulatory T lymphocytes that prevent excessive inflammatory responses and limit immune-mediated disease. This signaling depends, in part, on IL-27, a member of the IL-12 cytokine family that has been linked to IBD.

"Our study elucidates previously unexplored intercellular signals by which gut microbiota regulate the mucosal immune system to prevent disease," said lead study author Yoshiyuki Mishima, MD, PhD, University of North Carolina, Chapel Hill. "These findings potentially could be exploited to treat patients with IBD."

The role of B lymphocytes in producing protective antibodies that are secreted into the intestine is well-recognized. However, the contributions of B lymphocytes and their secreted products (other than antibodies) are not well understood. This mouse study shows that IL-10 and IL-27, which are secreted by B lymphocytes, regulate development of regulatory T lymphocytes.

"The work provides new insight into mechanisms by which gut bacteria drive mucosal immune homeostasis," added Jerrold R. Turner, MD, PhD, AGAF, editor-in-chief, Cellular and Molecular Gastroenterology and Hepatology.


Story Source:

Materials provided by American Gastroenterological Association. Note: Content may be edited for style and length.


Journal Reference:

  1. Yoshiyuki Mishima, Bo Liu, Jonathan J. Hansen, R. Balfour Sartor. Resident Bacteria-Stimulated Interleukin-10-Secreting B Cells Ameliorate T-Cell-Mediated Colitis by Inducing T-Regulatory-1 Cells That Require Interleukin-27 Signaling. CMGH Cellular and Molecular Gastroenterology and Hepatology, 2015; 1 (3): 295 DOI: 10.1016/j.jcmgh.2015.01.002

Cite This Page:

American Gastroenterological Association. "Research may provide new targets for inflammatory bowel diseases therapies." ScienceDaily. ScienceDaily, 15 June 2015. <www.sciencedaily.com/releases/2015/06/150615112651.htm>.
American Gastroenterological Association. (2015, June 15). Research may provide new targets for inflammatory bowel diseases therapies. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/06/150615112651.htm
American Gastroenterological Association. "Research may provide new targets for inflammatory bowel diseases therapies." ScienceDaily. www.sciencedaily.com/releases/2015/06/150615112651.htm (accessed May 23, 2017).

RELATED STORIES